Dr-COVID: Graph Neural Networks for SARS-CoV-2 Drug Repurposing
Siddhant Doshi and Sundeep Prabhakar Chepuri‚àó
The 2019 novel coronavirus (SARS-CoV-2) pandemic has resulted in more than a million deaths, high morbidities, and economic distress worldwide. There is an urgent need to

arXiv:2012.02151v1 [cs.LG] 3 Dec 2020

identify medications that would treat and prevent novel diseases like the 2019 coronavirus
disease (COVID-19). Drug repurposing is a promising strategy to discover new medical
indications of the existing approved drugs due to several advantages in terms of the costs,
safety factors, and quick results compared to new drug design and discovery. In this work,
we explore computational data-driven methods for drug repurposing and propose a dedicated
graph neural network (GNN) based drug repurposing model, called Dr-COVID. Although we
analyze the predicted drugs in detail for COVID-19, the model is generic and can be used for
any novel diseases. We construct a four-layered heterogeneous graph to model the complex
interactions between drugs, diseases, genes, and anatomies. We pose drug repurposing as a
link prediction problem. Specifically, we design an encoder based on the scalable inceptive
graph neural network (SIGN) to generate embeddings for all the nodes in the four-layered
graph and propose a quadratic norm scorer as a decoder to predict treatment for a disease.
We provide a detailed analysis of the 150 potential drugs (such as Dexamethasone, Ivermectin) predicted by Dr-COVID for COVID-19 from different pharmacological classes (e.g.,
corticosteroids, antivirals, antiparasitic). Out of these 150 drugs, 46 drugs are currently in
clinical trials. Dr-COVID is evaluated in terms of its prediction performance and its ability
to rank the known treatment drugs for diseases as high as possible. For a majority of the
diseases, Dr-COVID ranks the actual treatment drug in the top 15.

‚àó

The authors are with the Department of Electrical Communication Engineering, Indian Institute of Science, Bangalore, India.
Email:{siddhantd,spchepuri}@iisc.ac.in.

2
I.

INTRODUCTION

The dreadful pandemic outbreak of the coronavirus disease 2019 (COVID-19) has affected about 56
million people with more than a million deaths worldwide as of November 2020. The June 2020 Global
Economic Prospects [1] estimated a 5.2% downfall in the global gross domestic product (GDP) in 2020
that would lead to the worst economic slowdown in history after the Second World War. The disease affects
mammals‚Äô respiratory tract and shows symptoms similar to pneumonia, causing mild to severe respiratory
tract infections [2]. The pathogen that causes COVID-19 belongs to the Coronaviridae family, which is a
family of enveloped positive-strand RNA viruses that affect mammals, birds, and amphibians. The name
coronavirus (CoV) is derived because of the crown-shaped spikes that project from their surface. Coronaviruses are majorly grouped into four genera: alphacoronavirus, betacoronavirus, deltacoronavirus, and
gammacoronavirus. While deltacoronaviruses and gammacoronaviruses infect birds, alphacoronaviruses
and betacoronaviruses infect mammals [3]. Out of the seven known strains of human CoVs (HCoVs), the
three betacoronaviruses, namely, middle east respiratory syndrome coronavirus (MERS-CoV), severe acute
respiratory syndrome coronavirus (SARS-CoV), and the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) produce severe symptoms. In the past two decades, the world witnessed highly fatal
MERS-CoV and SARS-CoV that led to global epidemics with high mortality. Although the 2003 SARS-CoV
outbreak was controlled, it infected 8098 individuals and resulted in 774 deaths. As of November 2019,
2494 cases and 855 deaths were reported due to MERS-CoV, with the majority in Saudi Arabia [3]. In
December 2019, similar cases were again reported in Wuhan City, China [4], wherein investigations confirmed it to be the third novel CoV, i.e., SARS-CoV-2, which is also referred to as HCoV-2019, 2019-nCoV,
or colloquially simply as coronavirus [5]. SARS-CoV-2 being highly contagious, on 30 January 2020, the
World Health Organization (WHO) declared it as a public emergency of international concern warning all
the countries with vulnerable health care systems [6].
The current treatment for COVID-19 is completely supportive and symptomatic as there are no specific
known medicines. Several research groups around the world are trying to develop a vaccine that would
prevent and treat SARS-CoV-2. Looking at the current unpredictable trajectory of how the disease spreads
and the life cycle of the virus, there is an urgent need to develop preventive strategies against it. Given this
strict timeline, a more realistic solution lies in drug repurposing or drug repositioning, which aims to iden-

3
tify new medical indications of approved drugs. Drug repurposing offers several advantages. It has a low
risk of failure as the drug has already been approved with less unknown harmful adverse effects. It reduces
the time frame for drug development as the drugs have passed all the pre-clinical trials and safety norms.
Finally, compared to the discovery of a new drug, drug repurposing requires less economic investment and
puts fewer lives of volunteers (particularly kids) involved in clinical trials at risk [7]. Some of the examples
of repurposed drugs are Sildenafil, which was initially developed as an antihypertensive drug was proved
effective in treating erectile dysfunction by Pfizer [7], and Rituximab that was originally used against cancer was proved to be effective against rheumatoid arthritis [7], to name a few. Even for COVID-19, drugs
like Remdesivir (a drug for treating Ebola virus disease), Chloroquine/Hydroxychloroquine (antimalarial
drugs), Dexamethasone (anti-inflammatory drugs) are being repurposed and are under clinical trials as per
the International Clinical Trials Registry Platform (ICTRP), which is a common platform maintained by
WHO to track the clinical trial studies across the world.
Drug repurposing involves identifying potential drugs and monitoring their in vivo efficacy and potency
against the disease. The most critical step in this pipeline is identifying the right candidate drugs, for
which experimental and computational approaches are usually considered. To identify potential drugs experimentally, a variety of chromatographic and spectroscopic techniques are available for target-based drug
discovery. Phenotype screening is used as an alternative to target-based drug discovery when the identity
of the specific drug target and its role in the disease are not known [7]. Recently, computational approaches
are receiving attention due to the availability of large biological data. Efficient ways to handle big data has
opened up many opportunities in the field of pharmacology. Zitnik, et al. [8] elaborates several data-driven
computational tools to integrate large volumes of heterogeneous data and solve problems in pharmacology
such as drug-target interaction prediction (identify interactions between a drug and its target genes), drug
repurposing, and drug-drug interaction or side effect prediction, to list a few. Hence this field is known as
computational pharmacology. Many standard machine learning (ML) and deep learning (DL) techniques
have been applied in computational pharmacology. Drug-drug interaction was formulated as a binary classification problem and solved using ML techniques like random forest, support vector machines (SVM),
and naive bayes [9], and using DL models like deep multi-layer perceptrons and recurrent neural networks,
to name a few. DL techniques often outperform standard ML techniques [10, 11]. However, these methods lack the ability to capture the structural information in the data, specifically the connections between

4
different biological entities (e.g., interactions between drugs and genes or between drugs and diseases). A
natural and efficient way to represent such structural information is to construct a graph with nodes representing entities like drugs, genes, diseases, etc., and edges representing the complex interactions between
these entities. Graph neural networks (GNNs) capture the structural information by accounting for the
underlying graph structure while processing the data. Decagon, a GNN-based model designed for predicting the side effects of a pair of drugs has proved its capability by outperforming the non-graph based
machine learning models in terms of its prediction performance [12]. Similarly, drug repurposing has
been studied using computational methods such as signature matching methods, molecular docking, and
network-based approaches. Recently, network-based and machine learning approaches [13‚Äì17], and GNN
based approaches [18] and [19] have been proposed for drug repurposing.
In this work, we propose a GNN architecture for COVID-19 drug repurposing called Dr-COVID, which
is a dedicated model for drug repurposing. We formulate our problem by constructing a four-layered heterogeneous graph comprising drugs, genes, diseases, and anatomies. We then build a deep learning model
to predict the links between the drug and disease entities, where a link between a drug-disease entity suggests that the drug treats the disease. Specifically, Dr-COVID is based on the scalable inceptive graph
neural network (SIGN) architecture [20] for generating the node embeddings of the entities. We propose
a quadratic norm scoring function that rank orders the predicted drugs. All the network information and
node features are derived from the drug repurposing knowledge graph (DRKG) [21]. DRKG is a biological
knowledge graph compiled using several databases, and comprises entities like drugs, diseases, anatomies,
etc., and their connections. We leverage their generic set of low-dimensional embeddings that represent
the graph nodes and edges in the Euclidean space for training. We validate Dr-COVID‚Äôs performance on
the known drug-disease pairs. Although we present the results and analysis for COVID-19, Dr-COVID is
generic and is useful for any novel human diseases. From a list of 150 drugs predicted by Dr-COVID for
SARS-CoV-2, 46 drugs are currently in clinical trials. For a majority of diseases with known treatment, the
proposed Dr-COVID model ranks the approved treatment drugs in the top 15, which suggests the efficacy
of the proposed drug repurposing model. As we use the SIGN architecture that does many computations
beforehand, Dr-COVID is computationally efficient as compared to the other GNN-based methods [18, 19].
Specifically, in contrast to [18] we include additional entities such as anatomies as the side information in
our graph. This additional information provides indirect interactions between the disease and gene entities.

5
The norm scorer we design captures correlations between the drug and disease pairs, and as a consequence,
the model predicts many more drugs (e.g., Brexanolone) that are in clinical trials as compared to the existing
GNN-based and network-based drug repurposing models.

II.

RESULTS AND DISCUSSION

In this section, we present the drugs predicted by Dr-COVID for COVID-19 according to their pharmacological classifications, and elaborate on their roles in treating the disease. We individually predict drugs
for the 27 entities that specify the SARS-CoV-2 genome structure as identified by Gordon et al. [22]. This
genome structure includes structural proteins, namely, envelope (SARS-CoV2-E), membrane (SARS-CoV2M), nucleocapsid (SARS-CoV2-N), surface (SARS-CoV2-spike) proteins, 15 non-structural proteins (nsp),
and open reading frames (orf) that encode the accessory proteins. We also predict drugs for 6 diseases
related to CoV, namely, SARS-CoV, Avian infectious bronchitis virus (IBV), MERS-CoV, CoV-229E, CoVNL63, and Murine coronavirus (MHV). We choose the top 10 ranked predicted drugs for all these disease
targets, combine them, and present them as a single list of 150 drugs (after removing the duplicate entries).
We refer to these 33 (i.e., 27 entities related to the SARS-CoV-2 genome structure and 6 CoV diseases) as
COVID-19 nodes. Out of these 150 drugs, 46 drugs are in clinical trials in different phases. We provide the
predicted scores of all the drugs for all the COVID-19 nodes using Dr-COVID in our github repository. The
software to reproduce the results are available at: https://github.com/siddhant-doshi/Dr-COVID
Fig 1 gives a heatmap indicating the ranks of these 150 drugs. It is a matrix representation in which
the drugs are listed on the vertical axis and COVID-19 nodes on the horizontal axis. All the 150 drugs
are grouped based on their first-level anatomical therapeutic chemical (ATC) codes as indicated on the left
side. A colored patch in the heatmap indicates the rank of a drug for a disease. The darker the patch,
the better is the rank, as indicated by the rank bar on the right side. As can be seen, a major portion
of the heatmap is covered with dark patches as we only consider the top 10 ranked drugs. We can infer
from the heatmap that cardiovascular drugs (e.g., Captopril, Atenolol) and anti-inflammatory drugs (e.g.,
Celecoxib, Prednisone) are ranked high for the alphacoronaviruses, and a combination of antiparasitic
(e.g., Ivermectin), corticosteroids (e.g., Prednisolone, Dexamethasone), antivirals (e.g., Cidofovir), and
antineoplastic drugs (e.g., Methotrexate, Sirolimus) in the case of betacoronaviruses.

6

FIG. 1. Rank heatmap of the predicted drugs with their corresponding ATC labels.

7
Fig 2 lists the drugs predicted by Dr-COVID, grouped based on their first level ATC codes such as
antiparasitic (P), respiratory system (R), and so on, whereas Fig 1 emphasizes the ranks of these predicted
drugs for the COVID-19 nodes. The majority of the corticosteroids we predict belong to the respiratory
system (R) class, which has been the primary target for the coronaviruses, as reflected by the symptoms.
However, COVID-19 has a multi-organ impact on the human body and is not limited to the respiratory
system [23]. Complications due to the cytokine storm with the effects of angiotensin converting enzyme
(ACE) have led to cardiac arrest, kidney failure, and liver damage resulting in many deaths. For these
reasons, we see drugs from various ATC classes are being considered for clinical trials. Next, we discuss in
detail these pharmacological classifications of some of the predicted drugs.
Anti-inflammatory (AI) agents: Inflammatory cytokine storms are prominently evident in COVID19 positive patients and timely anti-inflammation treatment is required [24]. Pneumonia caused by the
coronavirus results in a huge amount of inflammatory cell infiltration leading to acute respiratory distress syndrome (ARDS), causing many deaths [25, 26]. A wide range of anti-inflammatory treatments
including glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs), immunosuppressants, inflammatory cytokines antagonists like tumor necrosis factor (TNF) inhibitors, Janus kinase (JAK) inhibitors, and
interleukin-1-receptor antagonist (IL-1RA) are being considered for COVID-19. Our model predicts in the
top 10, steroids like Dexamethasone, Hydrocortisone, Methylprednisolone; NSAIDs like Ibuprofen, Aspirin
(Acetylsalicylic acid); immunosuppressants like Sirolimus and Methotrexate; IL-1RA Anakinra; CoX2 inhibitor Celecoxib. These drugs are currently undergoing clinical trials. Some of the other corticosteroids
like Betamethasone, Prednisone, and TNF inhibitor Certolizumab pegol were also ranked high.
Antiviral and anti-parasitic agents: Dr-COVID predicts nucleotide analogue antivirals like Acyclovir,
Valaciclovir, Cidofovir, and Entecavir that have shown positive results in terminating the RNA synthesis catalyzed by polymerases of coronaviruses [27]. Ivermectin and Nitazoxanide are used against many
parasite infestations and are also known to have antiviral properties. Mebendazole is another similar antiparasitic drug that Dr-COVID ranked high. One of the recent reports shows that Ivermectin is an effective inhibitor of the SARS-CoV-2 and many other positive single-stranded RNA viruses. A 5000-fold reduction in
the virus titer within 48 hours in cell culture was obtained with a single treatment (5¬µM) of Ivermectin [28].
Statins and ACE inhibitors/ beta-blockers/ calcium channel blockers: Statins are lipid-lowering
drugs that inhibit the cholesterol synthesis enzyme (also known as HMG-CoA reductase), which also has

8

Alimentary and metabolism
(A)

Blood and blood forming
organs (B)

Cardiovascular System (C)
3

Agalsidase beta
Orlistat
Cholecalciferol4
Riboflavin
Sacrosidase
Prednisone4
Aluminum hydroxide
Sebelipase alfa
Taliglucerase alfa
Glyburide
OmeprazoleNA
Laronidase
Esomeprazole3
Nitisonone
Repaglinide

Systemic hormonal preparations
(H)
Somatotropin4
Rimexolone

Musculo skeletal system (M)
Ibuprofen4
Penicillamine
Ataluren
Celecoxib1
Cyclobenzaprine

Antiparasitic (P)
Ivermectin4
Pyrimethamine
Mebendazole
Proguanil
Nitazoxanide4
Permethrin
Diethyltoluamide

Simvastatin
Atorvastatin3
Spironolactone4
Nitroglycerin
ClonidineNA
AtenololNA
HydralazineNA
Furosemide
Fluocinonide
Etacrynic acid
Rosuvastatin3
Nifedipine4
Niacin3
Diazoxide
Propranolol3
Pentoxifylline2
Alprostadil2
Captopril3
Hydrochlorothiazide4

MecobalaminNA
Iron
Arginine
Acetylsalicylic acid3

Antineoplastic and
immunomodulating agents (L)
Paclitaxel
Cyclophosphamide
Aflibercept
Mercaptopurine
Cyclosporine4
Denileukin diftitox
Cladribine
Methotrexate2
Hydroxyurea
Chlorambucil
Flutamide
Sirolimus2
Pentostatin
Ocrelizumab
Rituximab
Abatacept2
Anakinra3
Mechlorethamine
Certolizumab pegol

Dermatologicals (D)
Alclometasone
Monobenzone
Diflorasone
Sulfacetamide
Hydroquinone
Methylprednisolone3
Tazarotene
Clocortolone
Desoximetasone
Imiquimod
Flumethasone
Becaplermin
Collagenase clostridium
Flurandrenolide
Benzyl peroxide
Finasteride3
Docosanol

Anti-infectives (J)
Genito-urinary systems and
sex hormones (G)
Fluoxymesterone
Sulfadoxine
Drospirenone
Levonorgestrel
Norethisterone
Danazol
Sulfacytine

Acyclovir1
Rifampicin
Ganciclovir
Rifapentine
Yellow fever vaccine
Valaciclovir
Entecavir
Cidofovir
Rubella virus vaccine3
Dapsone

Nervous System (N)
Dextroamphetamine
Desipramine
Bromocriptine
Valproic acid4
Phenobarbital
Armodafinil
Carbamazepine
Clonazepam
Amitriptyline
St. John‚Äôs Wort

Sensory Organs (S)
Respiratory System (R)
Epinephrine
Hydrocortisone4
Procaterol
Dexamethasone4
Benzocaine
Betamethasone
Prednisolone3

Miscellaneous
(ATC not available)

Denoside
Ranibizumab
Medrysone

Various (V)
Rsasburicase
Nitrogen2
Samarium lexidronam
Deferoxamine4

Human immunoglobulin G4
Ephedra sinica root
NADH
D-glucose4
Adenosine 5‚Äô-phosphosulfate
Dichlorobenzene
Tafenoquine2
Ebola Zaire virus vaccine
Hemin
Cysteine3
Human Rho(D) immune globulin
Serine
Aloe vera leaf
Brexanolone3
Varicella Zoster vaccine
ND7001
Thymol
Lancovutide
Crizanlizumab2
Onasemnogene abeparvovec

Drugx - The drug name in red indicates it is undergoing clinical trials and the x gives its current phase.
NA - Phase information not available

FIG. 2. Predicted drugs for COVID, categorized based on their ATC labels.

9
anti-inflammatory properties. There have been implications of lipid metabolism in the SARS-CoV-2 pathogenesis [29], due to which there are reports on including statins in the line of treatment for COVID-19.
Dr-COVID predicts Atorvastatin, Simvastatin, and Rosuvastatin, where all the three drugs are currently in
clinical trials. On the contrary, some studies show that statins tend to increase the cellular expression of
ACE inhibitors [30], to which the SARS-CoV2-spike protein binds at the entry-level in humans [31]. Analyzing this issue, an observational study by Zang et al. [32] reported a reduced mortality rate in the patients
treated with statins and no adverse effect was observed by adding an ACE inhibitor drug also to the line
of treatment. These ACE inhibitors are cardiovascular drugs causing relaxation of blood vessels that are
primarily used to treat high blood pressure and heart failure. Beta-adrenergic and calcium channel blockers
are other similar functioning drugs that lower blood pressure, are also currently considered to treat COVID19. Dr-COVID predicts Captopril (ACE inhibitor), Atenolol (beta-blocker) and Nifedipine (calcium channel
blocker), which are currently in clinical trials. Additionally, the list of predicted drugs includes Spironolactone and Hydrochlorothiazide, that help prevent our body from absorbing too much salt and eventually
lowering the blood pressure and avoiding cardiac failure.

Miscellaneous: Dr-COVID also predicts some of the pre-discovered vaccines such as Rubella virus vaccine, which is majorly considered for all the healthcare workers, the Yellow fever vaccine [33], and the
Ebola zaire virus vaccine (rVSV-ZEBOV). Further, we also have Mercaptopurine, an antineoplastic agent
that has been considered as a selective inhibitor of SARS-CoV [34] in the list of predicted drugs. Antidepressant Brexanolone that is currently considered for patients on ventilator support due to ARDS, vasodilators
Nitroglycerine and Alprostadil, nutritional supplements like Riboflavin (Vitamin B2 ) [35], Niacin, Cholecalciferol (Vitamin D3 ), and Iron are some more top-ranked drugs. Interestingly, Ephedra sinica root, a
herb generally used to treat asthma and lung congestion, and an ingredient of lung cleansing and detoxifying decoction (LCDD), which is a widely used traditional Chinese medicine [36] is one of the drugs
predicted in our list.

In essence, Dr-COVID predicts drugs for COVID-19 from different pharmacological classes like the
corticosteroids, antivirals, antiparasitic, NSAIDs, and cardiovascular drugs, as the disease does not target
particular anatomy and impacts multiple organs in the human body.

10
III.

DATASET

In this section, we describe the dataset that we use to train and test Dr-COVID for COVID-19 drug repurposing. We also describe how we model the data as a multilayer graph to capture the underlying complex
interactions between different biological entities. We derive the required information from DRKG, which
is a comprehensive biological knowledge graph relating genes, drugs, diseases, biological processes, side
effects, and other eight more entities useful for computational pharmacological tasks like drug repurposing, drug discovery, and drug adverse effect prediction, to list a few. DRKG gathers all this information
from six databases, namely, Drugbank [37], Hetionet [38], GNBR [39], STRING [40], IntAct [41], and
DGIdb [42]. From DRKG, we consider four entities that are relevant to the drug repurposing task. The
four entities are drugs (e.g., Dexamethasone, Sirolimus), diseases (e.g., Scabies, Asthma), anatomies (e.g.,
Bronchus, Trachea), and genes (e.g., Gene ID: 8446, Gene ID: 5529). All the genes are referred with their
respective Entrez IDs throughout the paper. We extract the details about these entities specifically from the
Drugbank, Hetionet, and GNBR databases. We form a four-layered heterogeneous graph with these four
entities in each layer as illustrated in Fig 3a. The four-layered graph is composed of 8070 drugs, 4166
diseases, 29848 genes, 400 anatomies, and a total of 1,417,624 links, which include all the inter-layer and
intra-layer connections. Next, we discuss the interactome that we consider for drug repurposing.
Interactome: There are inter-layered connections between the four layers and some have intra-layered
connections. The inter-layered connections are of different types. The drug-disease links indicate treatment
or palliation, i.e., a drug treats or has a relieving effect on a disease. For example, interaction between
Ivermectin-Scabies (as seen in Fig 3b) and Simvastatin-Hyperlipidemia (as seen in Fig 3d) are of type
treatment, whereas Atropine-Parkinson‚Äôs disease and Diclofenac-Osteoarthritis are of type palliation. The
drug-gene and disease-gene links are the direct gene targets of the compound and the disease, respectively.
Gene ID: 4306, Gene ID: 387, Gene ID: 1786 are some of the targets of the drug Dexamethasone (see
Fig 3b) and Gene ID: 5509, Gene ID: 859 are target genes of the disease Malaria. Some of the genes
targeted by the drug (e.g., Dexamthasone, Ivermectin, Simvastatin) as well as by the SARS-CoV-2 virus
(referred to as shared genes) are shown in Fig 3 (b,c and d). These common gene targets between a drug
and a disease are one of the reasons for the drug to be a potential repurposing candidate against the disease.
The disease-anatomy and gene-anatomy connections indicate how the diseases affect the anatomies and

11

Drugs

Diseases

(a)

(b)

(c)

(d)

Target genes of the drug

Shared genes between the drug and SARS-CoV-2

Anatomies

FIG. 3. (a) Four-layered heterogeneous graph illustrating the inter-layer and intra-layer connections. (b), (c) and (d)
Subgraph centered around the drugs Dexamethasone, Ivermectin and Simvastatin, respectively.

interactions between the genes and anatomies. For example, Gene ID: 2771 and Gene ID: 3156 belong
to the cardiac ventricle anatomy (see Fig 3d); disease Schizophrenia affects multiple anatomies like the
central nervous system (CNS) and optic tract.
There are also intra-layered connections. The drug-drug and disease-disease connections show the similarity between a pair of drugs and diseases, respectively. The gene-gene links describe the interaction
between genes (e.g., epistasis, complementation) and form the whole gene interactome network. This
comprehensive gene network serves as a backbone for our model, wherein we predict the unknown links

12
between drugs and new diseases like COVID-19 as they are connected through genes and anatomies. The
anatomy information helps in drug predictions by focusing on the local interactions of genes related to the
same anatomy as the genes targeted by the disease. Some examples of the intra-layered connections are
Simvastatin-Lovastatin and Gene ID: 23649-Gene ID: 8480 as seen in Fig 3d. While all these interactions
reveal the true relations between the entities, we also randomly sample the no-drug-disease links, which
give us negative control in the learning process. For example, there is no link between Simvastatin-Scabies,
i.e., Simvastatin is not known to treat or suppress the effects of Scabies. Including such negative control in
the training process makes our model accurate and reliable.
HCoV interactome network: To specialize the drug repurposing model Dr-COVID for COVID-19, as
discussed before, we consider the four known HCoVs, namely, SARS-CoV, MERS-CoV, CoV-229E and
CoV-NL63, and two non-human CoVs namely MHV, and IBV. We consider interactions of these disease
nodes with human genes. There are 129 links between these six disease nodes and the gene nodes [21]. In
addition, we consider all the 27 SARS-CoV-2 proteins (including the structured proteins, nsp, and orf) and
their 332 links connecting the target human genes as given by Gordon et al. [22]. In other words, there are
only disease-gene interactions available for these COVID-19 nodes. With this available information, we
train Dr-COVID to predict possible drug connections for these COVID-19 nodes.

IV.

METHODS AND MODELS

In the last few years, deep learning has gained significant attention from a variety of scientific disciplines due to its extraordinary successes in solving many challenging tasks like data cleansing, mining, and
classification, mainly for images, speech, or text datasets. However, in many applications, the structure
underlying data is not always Euclidean. Some examples include social networks, transportation networks,
brain networks, sensor networks, chemical molecules, protein-protein interactions, meshed surfaces in computer graphics, and the drug repurposing network, as discussed above, to list a few. For these applications,
more recently, deep learning for graph-structured data, also known as geometric deep learning (GDL) [43],
is receiving steady research attention. GDL aims at building neural network architectures known as graph
neural network (GNNs) to learn from graph-structured data. GDL models are used to learn low-dimensional
graph representations or node embeddings by taking into account the nodal connectivity information. These

13
embeddings are then used to solve many graph analysis tasks like node classification, graph classification,
and link prediction, to list a few. GNN architectures are developed using concepts from spectral graph
theory and generalize the traditional convolution operation in the convolutional neural network (CNN) to
the graph setting. In this section, we describe the proposed Dr-COVID architecture for COVID-19 drug
repurposing and describe numerical experiments performed to evaluate our model.
Consider an undirected graph G = (V , E ) with a set of vertices V = {v1 , v2 , ¬∑ ¬∑ ¬∑ , vN } and edges ei j ‚àà E
denoting a connection between nodes vi and v j . We represent a graph G using the adjacency matrix A ‚àà
RN√óN , where the (i, j)th entry of A denoted by ai j is 1 if there exists an edge between nodes vi and v j ,
and zero otherwise. To account for the non-uniformity in the degrees of the nodes, we use the normalized
1

1

adjacency matrix denoted by AÃÉ = D‚àí 2 AD‚àí 2 , where D ‚àà RN√óN is the diagonal degree matrix. Each node
in the graph is associated with its own feature vector (referred to as input feature). Let us denote the input
(0)

feature of node i by xi

‚àà Rd , which contains key information or attributes of that node (e.g., individual

drug side effects). Let X(0) ‚àà RN√ód be the input feature matrix associated with the N nodes in the graph G
obtained by stacking the input features of all the nodes in G . The new embeddings for a node is generated
by combining information from its neighboring nodes (e.g., diseases or genes) to account for the local
interactions. This process of combining information and generating new representations for a node is done
by a single GNN block. If we stack K such blocks, we can incorporate information for a node from its
K-hop neighbors (e.g., in Fig 3c, the drug Ivermectin is a 2-hop neighbor of the anatomy Lung and is
connected via Gene ID: 8614). Mathematically, this operation can be represented as
X(k+1) = gk (AÃÑX(k) Wk ),

(1)

where X(k) ‚àà RN√ódk represents the kth layer embedding matrix and dk is the embedding dimension in the kth
layer. Here, AÃÑ = I + AÃÉ, where the identity matrix I ‚àà RN√óN , is added to account for the self-node embeddings, Wk ‚àà Rdk √ódk+1 is the learnable transformation matrix, and gk (¬∑) is the activation function in the kth
layer. There exist several GNN variants such as graph convolutional networks (GCN) [44], GraphSAGE [45],
graph attention networks (GAT) [46] and scalable inception graph neural network (SIGN) [20], to name a
few. GCN is a vanilla flavored GNN based on Eq (1). GAT gives individual attention to the neighboring nodes
instead of treating every node equally. To address the issue of scalability, GraphSAGE uses a neighbor sam-

14
pling method, wherein instead of taking the entire neighborhood, we randomly sample a subset of neighbor
nodes. SIGN takes a different approach to solve the scalability issue and introduce a parallel architecture.
The proposed Dr-COVID architecture is based on the SIGN approach due to its computational advantages.
The predicted list of drugs from other GNNs are available in our repository. Next, we describe the proposed
Dr-COVID architecture.

A.

Dr-COVID architecture

The proposed GNN architecture for SARS-CoV-2 drug repurposing has two main components, namely,
the encoder and decoder. The encoder based on the SIGN architecture generates the node embeddings of
all the nodes in the four-layer graph. The decoder scores a drug-disease pair based on the embeddings.
The encoder and decoder networks are trained in an end-to-end manner. Next, we describe these two
components of the Dr-COVID architecture, which is illustrated in Fig 4.
Encoder: The Dr-COVID encoder is based on the SIGN architecture [20], which provides low-dimensional
node embeddings based on the input features and nodal connectivity information. Recall that the matrix A
is the adjacency matrix of the four-layered graph G and AÃÉ is the normalized adjacency. SIGN uses linear
diffusion operators represented using matrices Fr , r = 1, 2, ¬∑ ¬∑ ¬∑ , to perform message passing and aggregate
local information in the graph. By choosing Fr = AÃÉr we can incorporate information for node v from
its r-hop neighbors. Here, AÃÉr denotes the rth matrix power. To start the information exchange between
the nodes, we assume that each node has its own d dimensional feature, which we collect in the matrix
X ‚àà RN√ód to obtain the complete input feature matrix associated with the nodes of G . We can then represent
the encoder as
Z = œÉ1 {[XŒò0 k F1 XŒò1 k ¬∑ ¬∑ ¬∑ k Fr XŒòr ]}

and Y = œÉ2 {ZW} ,

(2)

where Y is the final node embedding matrix for the nodes in the graph G , and {Œò0 , ¬∑ ¬∑ ¬∑ , Œòr , W} are the
learnable parameters. Here, k represents concatenation and œÉ1 {¬∑} and œÉ2 {¬∑} are the nonlinear tanh and
1

1

leaky rectified linear unit (leaky ReLU) activation functions, respectively. The matrix Fr X = D‚àí 2 Ar D‚àí 2 X
captures information about the local interactions over r-hop neighbors. Fig 4 shows the encoder architec-

15

Individual node
information

Information from
1-hop neighbors

Information from
2-hop neighbors

Input features

ùöØ0

ùöØ1

ùöØ2

Drugs

Concatenate

Anatomies

Network learnable parameters

Diseases

W

Genes

Node embeddings

eas
e

g
Dru

Dis

indicates the -hop neighborhood of node

Decoder

Pr

(

,

)

FIG. 4. Dr-CoV architecture.

Drugs

Diseases

Anatomies

Genes

16
ture. The main benefit of using SIGN over other sequential models (e.g., GCN, GAT, GraphSAGE) is that
the matrix product Fr X is independent of the learnable parameters Œòr . Thus, this matrix product can be
pre-computed before training the neural network model. Doing so reduces the computational complexity
without compromising the performance.
In our setting, we choose r = 2, i.e., the low-dimensional node embeddings have information from 2-hop
neighbors. Choosing r ‚â• 3 is not useful for drug repurposing, as we aim to capture the local information
of the drug targets such that a drug node embedding should retain information about its target genes and
the shared genes in its vicinity. For example, the 1-hop neighbors of Dexamethasone as shown in Fig 3b,
are the diseases it treats (e.g., Asthma), and the drugs similar to Dexamethasone (e.g., Methylprednisolone)
and its target genes (e.g., Gene ID: 8446, Gene ID: 387). The 2-hop neighbors are the anatomies of the
target genes (e.g., Bronchus) of Dexamethasone, and the drugs that have similar effects on the diseases
(e.g., Hydrocortisone and Dexamethasone have similar effects on Asthma). It is essential for the embedding
related to Dexamethasone to retain this local information for the drug repurposing task, and not much
benefit is obtained by propagating more deeper in the network.
Decoder: For drug repurposing, we propose a score function that takes as input the embeddings of the
drugs and diseases and outputs a score based on which we decide if a certain drug treats the disease. Fig 4
illustrates the proposed decoder. The columns of the embedding matrix Y, contains the embeddings of all
the nodes in the four-layer graph, including the embeddings of the disease and drug nodes. Let us denote
the embeddings of the ith drug as yci ‚àà Rl and the embeddings of the jth disease as yd j ‚àà Rl . The proposed
scoring function f (¬∑) to infer whether drug ci is a promising treatment for disease d j is defined as

si j = f (yci , yd j ) = œÉ yTci Œ¶yd j ,

(3)

where œÉ {¬∑} is the nonlinear sigmoid activation function and Œ¶ ‚àà Rl√ól is a learnable co-efficient matrix.
We interpret si j as the probability that a link exists between drug ci and disease d j . The term yTci Œ¶yd j can
be interpreted as a measure of correlation (induced by Œ¶) between the disease and drug node embeddings.
We use d = 400 and l = 250 in our implementation. The model is trained in a mini-batch setting in an
end-to-end fashion using stochastic gradient descent to minimize the weighted cross entropy loss, where

17
the loss function for the sample corresponding to the drug-disease pair (i, j) is given by
 
`(si j , zi j ) = wzi j log

1
œÉ (si j )


+ 1 ‚àí zi j




1
,
log
1 ‚àí œÉ (si j )


(4)

where zi j is the known training label associated with score si j for the drug-disease pair, zi j = 1 indicates
that drug i treats disease j and otherwise when zi j = 0. Here, w is the weight on the positive samples that
we choose to account for the class imbalance. As discussed in the Dataset Section, we include the no-drugdisease links as negative control while training our model. The number of no-drug-disease links is almost
thirty times the number of positive samples. To handle this class disparity, we explicitly use a weight w > 0
on the positive samples.

B.

Model evaluation

In this subsection, we evaluate Dr-COVID and discuss the choice of various hyper-parameters. The drug
repurposing via link prediction can be viewed as a binary classification problem, wherein a positive class
represents the existence of a link between the input drug and disease, and otherwise for a negative class. We
have 6113 positive samples (drug-disease links) in our dataset. To account for the negative class samples,
we randomly choose 200,000 no-drug-disease links (i.e., there is no link between these drugs and diseases).
These links are then divided into the training and testing set with a 90% ‚àí 10% split. To use mini-batch
stochastic gradient descent, we group the training set in batches of size 512 and train them for 20 epochs.
Due to the significant class imbalance, we oversample the drug-disease links while creating batches, thus
maintaining the class ratio (ratio of the number of negative samples to the number of positive samples) of
1.5 in each batch. The weight w on the positives samples (mentioned in Eq (4)), is also chosen to be the
class imbalance ratio of each batch, i.e., we fix w to be 1.5.
We perform experiments on three sequential GNN encoder architectures, namely, GCN [44], GraphSAGE [45],
and GAT [46] for the drug repurposing task, which we treat as a link prediction problem, and compare with
the proposed Dr-COVID architecture. Specifically, the SIGN encoder in Dr-COVID is replaced with GCN,
GraphSAGE, and GAT to evaluate the model performance. Two blocks of these sequential models are
stacked to maintain the consistency with r = 2 of the Dr-COVID architecture. We evaluate these models

18

ROC Curves
1.0

True positive rate

0.8
0.6
0.4
SAGE AUROC = 0.958
GCN AUROC = 0.951
GAT AUROC = 0.942
Dr-CoV (SIGN) AUROC = 0.924
Random classifier = 0.5

0.2
0.0
0.0

0.2

0.4

0.6

False positive rate

0.8

1.0

FIG. 5. ROC Curves.

on the test set, which are known treatments for diseases that are not shown to the model while training.
The model is evaluated based on two performance measures. Firstly, we report the ability to classify the
links correctly, i.e., to predict the known treatments correctly for diseases in the test set. This is measured
through the receiver operating characteristic (ROC) curve of the true positive rate (TPR) versus the false
positive rates (FPR). Next, using the list of predicted drugs for the diseases in the test set, we report that
model‚Äôs ability to rank the actual treatment drug as high as possible (the ranking is obtained by ordering
the scores in Eq (3)).
ROC curves show the performance of a binary classification model by varying the threshold values used
to classify the positive samples, which eventually change the TPR and FPR. Fig 5 shows the ROC curves
of different GNN models. The area under ROC (AUROC), which lies in the interval [0,1] indicates the
separation ability of a binary classifier, where 1 indicates the best performance, 0.5 means that the model
is unable to discriminate between the classes and 0 indicates a completely opposite behavior. We can see
from Fig 5 that all the models have very similar AUROC values.
We also evaluate Dr-COVID in terms of ranks of the actual treatment drug in the predicted list for a
disease from the testing set, where the rank is computed by rank ordering the scores as before. In addition,
we compute the network proximity scores [13] and rank order the drugs based on these scores to compare

19
with other GNN encoder models. These network proximity scores are a measure of the shortest distance
between drugs and diseases. They are computed as
1
Pi j =
|C | + |T |

!
d(p, q)
‚àë min d(p, q) + ‚àë min
p‚ààC

p‚ààC q‚ààT

,

(5)

q‚ààT

where Pi j is a proximity score of drug ci and disease d j . Here, C is the set of target genes of ci , T is the
set of target genes of d j , and d(p, q) is the shortest distance between a gene p ‚àà C and a gene q ‚àà T in the
gene interactome. We convert these into Z-scores using the permutation test as
Zi j =

Pi j ‚àí ¬µ
,
œâ

(6)

where ¬µ is the mean proximity score of ci and d j , which we compute by randomly selecting subsets of
genes with the same degree distribution as that of C and T from the gene interactome, and œâ is the
standard deviation of the scores generated in the permutation test. Table I gives the rankings, which clearly
show that the Dr-COVID results in better ranks on the unseen diseases than the other GNN variants. Also,
compared to the network proximity measure, which is solely based on the gene interactome, Dr-COVID
performs better. We choose these drug-disease pairs for evaluation as these links are not shown during the
training. It is evident that the diseases on which we evaluate are not confined to single anatomy (e.g., rectal
neoplasms are associated to the rectum anatomy, whereas pulmonary fibrosis is a lung disease), nor do
they require a similar family of drugs for their treatment (e.g., Fluorouracil is an antineoplastic drug, and
Prednisone is an anti-inflammatory corticosteroid). Thus, showcasing our model‚Äôs unbiased nature. For a
majority of the diseases in the test set Dr-COVID ranks the treatment drug in top 10 (as seen in Table I).
In the case of Leukemia (blood cancer), other antineoplastic drugs like Hydroxyurea and Methotrexate are
ranked high (in top 10) and its known treatment drug Azacitidine is ranked 17. We give more importance
to the ranking parameter as any drug predictor requires classifying and ranking the correct drugs as high
as possible. Considering this AUROC-ranking trade-off we can see that Dr-COVID with SIGN encoder
performs the best.
COVID-19 analysis: We perform a similar analysis and identify potential candidate drugs for SARSCoV-2. For all the COVID-19 nodes in our dataset comprising 27 proteins (structured, nsp and orf), SARS-

20
Disease

Treatment drug

Ranks
Dr-CoV (SIGN)

SAGE

GCN

GAT

Network proximity

Encephalitis

Acyclovir

10

35

35

295

5462

Rectal neoplasms

Fluorouracil

9

421

16

231

2831

Pulmonary fibrosis

Prednisone

5

3

10

9

2072

Atrioventricular block

Atropine

6

79

8

14

4453

Pellagra

Niacin

2

56

497

484

Not computable

Colic

Hyoscyamine

1

1

501

205

Not computable

Leukemia

Azacitidine

17

120

31

332

377

TABLE I. Ranking Table. The Table gives the ranking performance of Dr-COVID compared with other GNN variants and the network proximity measures. There are no associated genes with some of the disease in our database,
which makes it impossible to compute the Z scores. These are indicated as ‚ÄúNot computable". The best results are
highlighted in bold font.

CoV, IBV, MERS-CoV, CoV-229E, CoV-NL63, and MHV, we individually predict the drugs for all these 33
entities. Each protein in SARS-CoV-2 targets a different set of genes in humans, so we give individual predictions. We then pick the top 10 drugs from all the predicted drugs and list 150 candidate repurposed drugs
for COVID-19. Out of these 150 drugs, 46 are currently in clinical trials. Our predictions have a mixture
of antivirals, antineoplastic, corticosteroids, monoclonal antibodies (mAb), non-steroidal anti-inflammatory
drugs (NSAIDs), ACE inhibitors, and statin family of drugs, and some of the vaccines discovered previously
for other diseases. Refer to the Results Section for a detailed discussion on the analysis of the predicted
drugs for COVID-19.

V.

CONCLUSIONS

In this work, we presented a generalized drug repurposing model, called Dr-COVID for novel human
diseases. We constructed a biological network of drugs, diseases, genes, and anatomies and formulated the
drug repurposing task as a link prediction problem. We proposed a graph neural network model, which was
then trained to predict drugs for new diseases. Dr-COVID predicted 150 potential drugs for COVID-19, of
which 46 drugs are currently in clinical trials. The considered GNN model is computationally efficient and
better ranks known treatment drugs for diseases than the other GNN variants and non-deep methods like
the network proximity approaches. This work can be extended along several directions. Considering the

21
availability of substantial biological data, the inclusion of information like individual side effects of drugs,
the molecular structure of the drugs, etc., may further improve the predictions. Considering the comorbidities of a patient would help us analyze the biological process and gene interactions in the body specific to
an individual and accordingly prescribe the line of treatment. Predicting a synergistic combination of drugs
for a disease would be another area of interest where graph neural networks can be beneficial.

ACKNOWLEDGEMENTS

S.P. Chepuri is supported in part by the Pratiskha Trust Young Investigator Award, Indian Institute of
Science, Bangalore, and the SERB grant SRG/2019/000619, and S. Doshi is supported by the Robert Bosch
Center for Cyber Physical Systems, Indian Institute of Science, Bangalore, Student Research Grant 2020M-11 .
The authors thank the Deep Graph Learning team for compiling DRKG and making the data public at
https://github.com/gnn4dr/DRKG.

DATA AND CODE AVAILABILITY

All the implementation and the data required to reproduce the results in the paper are available at https:
//github.com/siddhant-doshi/Dr-COVID.

[1] World Bank. Global Economic Prospects, June 2020; 2020b. http://hdl.handle.net/10986/33748.
[2] Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses‚Äîdrug discovery and therapeutic options. Nat
Rev Drug Discov. 2016;15(5):327‚Äì347.
[3] Paules CI, Marston HD, Fauci AS.

Coronavirus infections‚Äîmore than just the common cold.

JAMA.

2020;323(8):707‚Äì708.
[4] Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and
the miracle. J Med Virol. 2020;92(4):401‚Äì402.

22
[5] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of
2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507‚Äì513.
[6] Sohrabi C, Alsafi Z, O‚ÄôNeill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares
global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71‚Äì76.
[7] Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges
and recommendations. Nat Rev Drug Discov. 2018;18(1):41‚Äì58.
[8] Zitnik M, Nguyen F, Wang B, Leskovec J, Goldenberg A, Hoffman M. Machine learning for integrating data in
biology and medicine: Principles, practice, and opportunities. Inf Fusion. 2019;50:71‚Äì91.
[9] Cheng F, Zhao Z. Machine learning-based prediction of drug‚Äìdrug interactions by integrating drug phenotypic,
therapeutic, chemical, and genomic properties. J Am Med Inform Assoc. 2014;21(e2):e278‚Äìe286.
[10] Yi Z, Li S, Yu J, Tan Y, Wu Q, Yuan H, et al. Drug-drug interaction extraction via recurrent neural network with multiple attention layers. International Conference on Advanced Data Mining and Applications.
2017;10604:554‚Äì566.
[11] Deng Y, Xu X, Qiu Y, Xia J, Zhang W, Liu S. A multimodal deep learning framework for predicting drug-drug
interaction events. Bioinformatics. 2020;36(15):4316‚Äì4322.
[12] Zitnik M, Agrawal M, Leskovec J. Modeling polypharmacy side effects with graph convolutional networks.
Bioinformatics. 2018;34(13):i457‚Äìi466.
[13] Cheng F, Desai RJ, Handy DE, Wang R, Schneeweiss S, Bar√°basi AL, et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat Commun. 2018;9(1):1‚Äì12.
[14] Guney E, Menche J, Vidal M, Bar√°basi AL. Network-based in silico drug efficacy screening. Nat Commun.
2016;7(1):1‚Äì13.
[15] Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus
2019-nCoV/SARS-CoV-2. Cell Discov. 2020;6(1):1‚Äì18.
[16] Cheng F, Lu W, Liu C, Fang J, Hou Y, Handy DE, et al. A genome-wide positioning systems network algorithm
for in silico drug repurposing. Nat Commun. 2019;10(1):1‚Äì14.
[17] Gramatica R, Di Matteo T, Giorgetti S, Barbiani M, Bevec D, Aste T. Graph theory enables drug repurposing‚Äìhow a mathematical model can drive the discovery of hidden mechanisms of action. PLOS One.
2014;9(1):e84912.

23
[18] Gysi DM, Valle √çD, Zitnik M, Ameli A, Gan X, Varol O, et al. Network medicine framework for identifying
drug repurposing opportunities for COVID-19 arXiv:1403.3301 [Preprint]. 2020 [cited 2020 Nov 20]. Available
from: https://arxiv.org/abs/2004.07229.
[19] Ioannidis VN, Zheng D, Karypis G. Few-shot link prediction via graph neural networks for Covid-19 drugrepurposing arXiv:2007.10261 [Preprint]. 2020 [cited 2020 Nov 20]. Available from: https://arxiv.org/
abs/2007.10261.
[20] Rossi E, Frasca F, Chamberlain B, Eynard D, Bronstein M, Monti F. SIGN: Scalable Inception Graph Neural
Networks arXiv:2004.11198 [Preprint]. 2020 [cited 2020 Nov 20]. Available from: https://arxiv.org/abs/
2004.11198.
[21] Ioannidis VN, Song X, Manchanda S, Li M, Pan X, Zheng D, et al. DRKG - Drug Repurposing Knowledge
Graph for Covid-19 2020 [cited 2020 Nov 20]. Database: Github [Internet]. Available from: https://github.
com/gnn4dr/DRKG/.
[22] Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction
map reveals targets for drug repurposing. Nature. 2020;583:459‚Äì468.
[23] Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multi-organ response. Curr Prob Cardiology.
2020;45(8):100618.
[24] Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment
of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from
China. Clin Immunol. 2020;214:108393.
[25] Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine
storm and immunopathology. Semin Immunopathol. 2017;39(5):529‚Äì539.
[26] Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39(5):517‚Äì528.
[27] Jockusch S, Tao C, Li X, Anderson TK, Chien M, Kumar S, et al. Library of Nucleotide Analogues Terminate
RNA Synthesis Catalyzed by Polymerases of Coronaviruses Causing SARS and COVID-19. Antiviral Res.
2020;180:104857.
[28] Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.

24
[29] Fajgenbaum DC, Rader DJ. Teaching old drugs new tricks: statins for COVID-19? Cell Metab. 2020;32(2):145‚Äì
147.
[30] Shin YH, Min JJ, Lee JH, Kim EH, Kim GE, Kim MH, et al. The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts. Heart Vessels.
2016;32(5):618‚Äì627.
[31] Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586‚Äì590.
[32] Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, Yuan Y, et al. In-hospital use of statins is associated with a
reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020;32(2):176‚Äì187.
[33] Rega Institute, Belgian University KU Leuven. KU Leuven Breakthrough as Modified Yellow Fever Virus Destroys COVID-19 in Preclinical Animal Research: Clinical Trials Next. News article. 2020 [cited 2020 Nov 19].
Available from: https://www.trialsitenews.com/ku-leuven-breakthrough-as-modified-yellowfever-virus-destroys-covid-19-in-preclinical-animal-research-clinical-trials-next/.
[34] Chen X, Chou CY, Chang GG. Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus
papain-like protease, a deubiquitinating and deISGylating enzyme. Antivir Chem Chemother. 2009;19(4):151‚Äì
156.
[35] Ragan I, Hartson L, Pidcoke H, Bowen R, Goodrich R. Pathogen reduction of SARS-CoV-2 virus in plasma and
whole blood using riboflavin and UV light. PLOS One. 2020;15(5):e0233947.
[36] Weng JK. Plant Solutions for the COVID-19 Pandemic and Beyond: Historical Reflections and Future Perspectives. Mol Plant. 2020;13:803‚Äì807.
[37] Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. Drugbank 5.0: a major update to the
Drugbank database for 2018. Nucleic Acids Res. 2017;46(D1):D1074‚ÄìD1082.
[38] Himmelstein DS, Lizee A, Hessler C, Brueggeman L, Chen SL, Hadley D, et al. Systematic integration of
biomedical knowledge prioritizes drugs for repurposing. eLife. 2017;6:e26726.
[39] Percha B, Altman RB.

A global network of biomedical relationships derived from text. Bioinformatics.

2018;34(15):2614‚Äì2624.
[40] Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein‚Äìprotein
association networks with increased coverage, supporting functional discovery in genome-wide experimental

25
datasets. Nucleic Acids Res. 2019;47(D1):D607‚ÄìD613.
[41] Orchard S, Ammari M, Aranda B, Breuza L, Briganti L, Broackes-Carter F, et al. The MIntAct project‚ÄîIntAct
as a common curation platform for 11 molecular interaction databases. Nucleic Acids Res. 2014;42(D1):D358‚Äì
D363.
[42] Cotto KC, Wagner AH, Feng YY, Kiwala S, Coffman AC, Spies G, et al. GIdb 3.0: a redesign and expansion of
the drug‚Äìgene interaction database. Nucleic Acids Res. 2018;46(D1):D1068‚ÄìD1073.
[43] Bronstein MM, Bruna J, LeCun Y, Szlam A, Vandergheynst P. Geometric deep learning: going beyond euclidean
data. IEEE Signal Process Mag. 2017;34(4):18‚Äì42.
[44] Kipf TN, Welling M. Semi-supervised classification with graph convolutional networks. arXiv:1609.02907
[Preprint]. 2016 [cited 2020 Nov 20]. Available from: https://arxiv.org/abs/1609.02907.
[45] Hamilton W, Ying Z, Leskovec J. Inductive representation learning on large graphs. Advances in NeurIPS. 2017
(pp. 1024-1034).
[46] VelicÃåkovicÃÅ P, Cucurull G, Casanova A, Romero A, Lio P, Bengio Y. Graph attention networks. arXiv:1710.10903
[Preprint]. 2017 [cited 2020 Nov 20]. Available from: https://arxiv.org/abs/1710.10903.

